Peter Singer
@petersinger.bsky.social
Professor Emeritus, University of Toronto. Former Special Advisor to WHO Director General; Co-founder of Grand Challenges Canada and University of Toronto Joint Centre for Bioethics. My blog: singerp.substack.com
Reposted by Peter Singer
The WHO listing is a step in the right direction. But it’s only advice to governments. Its indications are also pretty conservative: diabetes w/ heart or kidney disease or w/ obesity. WHO could speed up availability by pre-qualifying GLP-1 manufacturers and updating its clinical guidelines.
2/n
2/n
September 6, 2025 at 2:43 AM
The WHO listing is a step in the right direction. But it’s only advice to governments. Its indications are also pretty conservative: diabetes w/ heart or kidney disease or w/ obesity. WHO could speed up availability by pre-qualifying GLP-1 manufacturers and updating its clinical guidelines.
2/n
2/n
Reposted by Peter Singer
Funding is also needed. @natashaloder.bsky.social & I outline several options for innovative finance for GLP-1 drugs and sketch the huge opportunity as the patent on semaglutide expires in many jurisdictions early next year. Check out our joint piece here: open.substack.com/pub/singerp/...
3/n
3/n
The $6 revolution. How generic weight loss drugs could save millions of lives.
The arrival of generic semaglutide is an unheard of opportunity for global public health
open.substack.com
September 6, 2025 at 2:46 AM
Funding is also needed. @natashaloder.bsky.social & I outline several options for innovative finance for GLP-1 drugs and sketch the huge opportunity as the patent on semaglutide expires in many jurisdictions early next year. Check out our joint piece here: open.substack.com/pub/singerp/...
3/n
3/n
@natashaloder.bsky.social and I will have more to say about this and other global health stuff in the weeks ahead. Follow us on our substacks.
Natasha’s substack: open.substack.com/pub/overmatt...
Peter’s substack: open.substack.com/pub/singerp?...
4/4 fin
Natasha’s substack: open.substack.com/pub/overmatt...
Peter’s substack: open.substack.com/pub/singerp?...
4/4 fin
Overmatter | Natasha Loder | Substack
Stories that matter. Click to read Overmatter, by Natasha Loder, a Substack publication with hundreds of subscribers.
open.substack.com
September 6, 2025 at 2:47 AM
@natashaloder.bsky.social and I will have more to say about this and other global health stuff in the weeks ahead. Follow us on our substacks.
Natasha’s substack: open.substack.com/pub/overmatt...
Peter’s substack: open.substack.com/pub/singerp?...
4/4 fin
Natasha’s substack: open.substack.com/pub/overmatt...
Peter’s substack: open.substack.com/pub/singerp?...
4/4 fin
Funding is also needed. @natashaloder.bsky.social & I outline several options for innovative finance for GLP-1 drugs and sketch the huge opportunity as the patent on semaglutide expires in many jurisdictions early next year. Check out our joint piece here: open.substack.com/pub/singerp/...
3/n
3/n
The $6 revolution. How generic weight loss drugs could save millions of lives.
The arrival of generic semaglutide is an unheard of opportunity for global public health
open.substack.com
September 6, 2025 at 2:46 AM
Funding is also needed. @natashaloder.bsky.social & I outline several options for innovative finance for GLP-1 drugs and sketch the huge opportunity as the patent on semaglutide expires in many jurisdictions early next year. Check out our joint piece here: open.substack.com/pub/singerp/...
3/n
3/n